The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of tyrosine kinase inhibitors (TKI) after combination ipilimumab plus nivolumab (I/N) in metastatic clear cell renal cell carcinoma (ccmRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).
 
Austin Kalirai
No Relationships to Disclose
 
Isaiah Joy
No Relationships to Disclose
 
Sunita Ghosh
No Relationships to Disclose
 
Christian K. Kollmannsberger
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen Oncology; Merck; Merck KGaA; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Gilead Sciences; Ipsen; Janssen; Merck; Merck KGaA; Pfizer
Travel, Accommodations, Expenses - Ipsen; Pfizer
 
Aaron Richard Hansen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Merck; Novartis
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Neoleukin Therapeutics (Inst); Pfizer/EMD Serono (Inst); Roche/Genentech (Inst)
 
Myuran Thana
No Relationships to Disclose
 
Jeffrey Graham
Honoraria - Ipsen; Janssen Oncology; Pfizer
 
Daniel Yick Chin Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
 
Vincent Castonguay
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Janssen; Novartis
 
Georg A. Bjarnason
Stock and Other Ownership Interests - Merck
Honoraria - Bristol-Myers Squibb; Eisai; Ipsen; Merck; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer
Research Funding - Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Rodney H. Breau
No Relationships to Disclose
 
Anil Kapoor
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; Ipsen; Janssen Oncology; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst)
 
Frederic Pouliot
Stock and Other Ownership Interests - Allogene Therapeutics
Honoraria - Abbvie; Amgen; Astellas Pharma; Bayer; Ferring; Genzyme; Janssen; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Genzyme; Janssen; Pfizer; Progenics; Sanofi
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Janssen; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer; Janssen (Inst); Sanofi (Inst); Tersera (Inst)
Patents, Royalties, Other Intellectual Property - Transcriptional system and uses therof for single cell detection
Other Relationship - Merck; Progenics
 
Lori Wood
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Pfizer (Inst); Roche Canada (Inst)
 
Naveen S. Basappa
Honoraria - Astellas Pharma; Eisai; Ipsen; Janssen; Merck; Pfizer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Ipsen; Janssen; Merck; Pfizer; Roche Canada